Everything about sevoflurane for md Anaesthesia exam with it’s effect on each system pharmacology contraindicated indication what care to be taken

Reading File
Now let me search the medical library for comprehensive sevoflurane content in parallel.
Finding Sources
Finding Sources
Searching PubMed

sevoflurane anaesthesia pharmacology

Excellent sources found. Now let me read the key sections in parallel - Miller's, Goodman & Gilman's, Morgan & Mikhail's, and Barash's.
Reading File
Reading File
Reading File
Reading File
Now let me get more content - Morgan & Mikhail's sevoflurane section, Goodman & Gilman's full section, Miller's pharmacology block, and Lippincott for the pharmacology summary.
Reading File
Reading File
Reading File
Finding Sources
Let me get the drug interactions, malignant hyperthermia, and the Morgan & Mikhail section continuation.
Reading File
Finding Sources
Finding Sources
Let me get the pharmacology properties table and Miller's block 27 for more details on sevoflurane.
Reading File
Reading File
I now have comprehensive data from 5 major anesthesia textbooks. Let me compile the complete answer.

Sevoflurane - Complete Anaesthesia Exam Review


1. BASIC PHARMACOLOGY & PHYSICAL PROPERTIES

PropertyValue
Chemical classFluorinated methyl isopropyl ether (completely fluorinated)
Physical stateClear, colorless volatile liquid at room temp
Blood:gas partition coefficient0.65-0.69
Brain:blood partition coefficient1.7
MAC (adults, 100% O2)2.0% (1.71-2.05%)
MAC awake~0.6%
MAC in neonates~3.3%
MAC in elderly (>65 yrs)~1.5%
Vapor pressure (20°C)~157 mmHg
Vaporizer typeConventional variable-bypass vaporizer
Metabolism2-5% by hepatic CYP2E1
FlammabilityNon-flammable, non-explosive
OdorSweet, non-pungent
Boiling point58.5°C
PreservativeNone required (stored in sealed amber bottle)
  • Morgan & Mikhail's Clinical Anesthesiology, 7e - p. 312
  • Katzung's Basic & Clinical Pharmacology, 16e - Table 25-1
MAC modifiers:
  • MAC is reduced by: increasing age, hypothermia, hypotension (MAP <50), pregnancy, prior opioids, N2O (additive), benzodiazepines, alpha-2 agonists, hypoxia, metabolic acidosis
  • MAC is increased by: infants (peak ~6 months), hyperthermia, chronic alcohol use, chronic opioid use, red hair (possibly)

2. MECHANISM OF ACTION

Sevoflurane produces general anesthesia primarily by:
  1. Potentiation of GABA-A receptors - enhances inhibitory Cl- conductance
  2. Inhibition of NMDA receptors - reduces excitatory glutamate signaling
  3. Activation of 2-pore domain K+ channels (TREK/TASK) - hyperpolarizes neurons
  4. Inhibition of voltage-gated Na+ and Ca2+ channels
  5. Potassium channel (Shaker-family Kv1.2) interactions have also been demonstrated
The overall effect is generalized CNS depression with dose-dependent loss of consciousness, amnesia, and immobility.

3. PHARMACOKINETICS

Induction: Rapid - due to low blood:gas solubility (0.65). Alveolar concentration rises quickly toward inspired concentration.
  • Induction: 2-4% inhaled concentration (can use 4-8% with N2O for 1-min induction)
Distribution: Low solubility means minimal uptake into blood/tissues - rapid changes in anesthetic depth.
Metabolism: ~5% metabolized by CYP2E1 in the liver (10-25x more than isoflurane/desflurane).
  • Major metabolite: hexafluoroisopropanol (HFIP) - conjugated to glucuronide
  • Also produces inorganic fluoride (F-): serum levels average 22-31 µmol/L (exceed 50 µmol/L in ~7% of patients, but no clinical renal toxicity)
  • NOT metabolized to trifluoroacetate - so no immune-mediated hepatitis
Elimination: Predominantly via lungs (exhaled unchanged). Emergence is rapid - more rapid than isoflurane, slightly slower than desflurane.

4. EFFECTS ON ORGAN SYSTEMS

A. Cardiovascular System

  • Concentration-dependent decrease in arterial BP - due to decreased systemic vascular resistance (SVR) and mild myocardial depression
  • No tachycardia (unlike isoflurane/desflurane) - cardiac output less well maintained
  • Mild myocardial contractility depression - less than halothane
  • BP falls slightly less than with isoflurane or desflurane
  • QT interval prolongation - clinical significance uncertain; can persist 60 min post-emergence in infants
  • Does NOT sensitize myocardium to catecholamine-induced arrhythmias (unlike halothane)
  • Coronary vasodilation - half as potent as isoflurane (less "coronary steal" risk)
  • Ischemic preconditioning - provides myocardial protection (may reduce ischemia-reperfusion injury)

B. Respiratory System

  • Concentration-dependent respiratory depression: decreased tidal volume, increased respiratory rate in spontaneous breathing - net effect: reduced minute ventilation, raised PaCO2
  • Non-irritating to airway - no coughing, breath-holding, or laryngospasm on induction
  • Most potent bronchodilator of all volatile anesthetics (best for asthma patients)
  • Does not increase secretions
  • Decreases hypoxic pulmonary vasoconstriction (HPV) - can worsen V/Q mismatch

C. Central Nervous System

  • Decreases CMRO2 (cerebral metabolic rate) - dose-dependent
  • Decreases cerebrovascular resistance (CVR), can mildly increase CBF and ICP at normocarbia (>1.5 MAC more pronounced)
  • The response to hypocapnia is preserved - hyperventilation can counteract ICP rise
  • Does NOT cause seizure activity (unlike enflurane) - seizures not reported with sevoflurane
  • Emergence delirium (agitation) - especially in children; short-lived, no long-term sequelae
    • Strategies to prevent: fentanyl 1 µg/kg, propofol, ketamine, or alpha-2 agonists (dexmedetomidine)

D. Neuromuscular System

  • Potentiates non-depolarizing neuromuscular blockers (NMBAs) - dose-dependent enhancement
  • Produces adequate muscle relaxation for intubation at high concentrations after inhalational induction
  • Trigger for malignant hyperthermia (MH) in susceptible individuals

E. Renal System

  • Slight decrease in renal blood flow
  • Compound A (fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether) - formed by degradation in CO2 absorbents:
    • Nephrotoxic in rats (proximal tubular necrosis at >150 ppm-hours)
    • NOT clinically nephrotoxic in humans (human kidneys have far lower renal beta-lyase activity)
    • Peak compound A: ~20 ppm with soda lime, ~30 ppm with Baralyme at 1 L/min FGF
    • FDA recommendation: FGF ≥1-2 L/min; limit exposure to ≤2 MAC-hours
  • Serum fluoride rise: peaks around 22-31 µmol/L - no renal concentrating defect

F. Hepatic System

  • Decreases portal vein blood flow but increases hepatic artery blood flow - total hepatic blood flow maintained
  • NOT hepatotoxic - not metabolized to trifluoroacetate, so no immune hepatitis (unlike halothane)
  • No reported hepatic toxicity in clinical use

G. Uterine/Obstetric

  • Uterine relaxation (tocolytic effect) in a dose-dependent manner - can increase bleeding during Caesarean section at >1 MAC
  • Crosses placenta - fetal exposure possible; safe in low doses for obstetric procedures

5. INDICATIONS

  1. Inhalational induction of anaesthesia - especially in children and needle-phobic adults (preferred over all other volatile agents due to non-pungency)
  2. Maintenance of anaesthesia - after IV or inhalational induction
  3. Ambulatory/day-case surgery - rapid emergence, early discharge
  4. Paediatric anaesthesia - agent of choice
  5. Asthma patients - best bronchodilator among volatiles
  6. Patients at risk for myocardial ischemia - less tachycardia than isoflurane/desflurane
  7. Volatile Induction and Maintenance Anaesthesia (VIMA)
  8. Rapid sequence inhalational induction - 4-8% with 50% N2O achieves unconsciousness in ~1 min

6. CONTRAINDICATIONS

ContraindicationReason
Susceptibility to Malignant Hyperthermia (MH)Potent trigger - causes uncontrolled skeletal muscle Ca2+ release via RyR1 receptor
Severe hypovolemia/haemodynamic instabilityFurther reduces SVR and BP - can cause cardiovascular collapse
Intracranial hypertension (raised ICP)Dilates cerebral vessels, increases CBF and ICP at normocarbia
Previous unexplained severe adverse reaction to volatile agent (suspected)Caution; though halothane hepatitis risk is absent, individual reactions possible
From Morgan & Mikhail's Clinical Anesthesiology, 7e, p. 314

7. SPECIAL PRECAUTIONS & CARE TO BE TAKEN

Malignant Hyperthermia (MH)

  • Sevoflurane is a potent MH trigger - ABSOLUTELY CONTRAINDICATED in MH-susceptible patients
  • In MH-susceptible patients: use a vapour-free/clean anaesthesia machine (flush with high-flow O2 for 10-20 min to wash out residual vapour)
  • Have dantrolene immediately available

CO2 Absorbent / Compound A

  • Desiccated soda lime or Baralyme dramatically increases compound A production
  • Avoid running dry O2/N2O through circuit overnight
  • Use calcium hydroxide-only absorbents (Amsorb, Dragersorb free) to minimize compound A
  • Maintain FGF ≥ 2 L/min for anaesthetics lasting >2-3 hours
  • Risk of fire/explosion in circuit if desiccated CO2 absorbent is present (exothermic reaction); also produces CO

Renal Precaution

  • Fluoride-mediated nephrotoxicity: no clinical significance seen, but avoid prolonged low-flow anaesthesia in pre-existing renal impairment
  • FDA: limit exposure to <2 MAC-hours at low FGF

Paediatric - Emergence Delirium

  • Warn parents; not long-lasting
  • Prevention: adequate analgesia + consider fentanyl, dexmedetomidine, or propofol at end of case

Obstetric

  • Use at ≤1 MAC to minimize uterine relaxation and excessive blood loss

Cardiac

  • QTc prolongation risk - caution in patients on drugs that prolong QT interval (Class Ia/III antiarrhythmics, tricyclics)
  • Use with care in severe aortic stenosis (BP-dependent states)

Epilepsy

  • Sevoflurane does not cause epileptiform activity - generally safe, but high-dose (>1.5 MAC) spike-wave activity has been reported

Endocrinology

  • Avoid in suspected phaeochromocytoma only if combined with epinephrine (though sevoflurane itself does not sensitize - contrast with halothane)

8. DRUG INTERACTIONS

DrugInteraction
Non-depolarizing NMBAs (vecuronium, rocuronium, atracurium)Potentiated - reduce NMBA dose by ~30-40%
Nitrous oxide (N2O)Additive MAC reduction - reduces sevoflurane requirement
OpioidsReduce MAC (additive effect); increase PONV risk
EpinephrineSevoflurane does NOT sensitize heart to arrhythmias - safe to use epinephrine (unlike halothane)
Beta-blockers / antihypertensivesAdditive hypotension
QT-prolonging drugsAdditive QT prolongation
Inducers of CYP2E1 (ethanol, isoniazid, phenobarbital)Increased metabolism → higher fluoride production
MAO inhibitorsCaution - potential for haemodynamic instability

9. CLINICAL USE SUMMARY

FeatureDetail
Induction concentration2-4% (maintenance); 4-8% (rapid induction)
Maintenance concentration1-3% (with O2 or O2/N2O)
MAC awake~0.6%
Time to induction< 1-2 min (inhalational)
EmergenceRapid - earlier than isoflurane
PONVHigher than propofol TIVA; lower if opioids avoided
AdvantagesNon-pungent, best bronchodilator, rapid, no arrhythmia sensitization, no hepatotoxicity
DisadvantagesEmergence delirium (children), compound A, mild QT prolongation, uterine relaxation

10. COMPARISON SNAPSHOT (Exam Table)

PropertySevofluraneIsofluraneDesfluraneHalothane
Blood:gas coeff0.651.40.422.3
MAC (%)2.01.156-70.75
VaporizerStandardStandardHeated/pressurizedStandard
Inhalational inductionExcellentPoor (pungent)Poor (pungent)Good
Metabolism5%<2%<0.05%>40%
HepatotoxicityNoRareNoYes (halothane hepatitis)
Arrhythmia sensitizationNoMinimalNoYes
BronchodilationBestGoodGoodGood
Compound AYesNoNoNo
MH triggerYesYesYesYes

11. HIGH-YIELD EXAM POINTS

  • Non-pungent = preferred for inhalational induction (especially paediatrics)
  • Most potent bronchodilator of volatile anaesthetics
  • No tachycardia = preferred in patients with IHD/tachyarrhythmias
  • Does NOT sensitize myocardium to catecholamines - can safely use epinephrine
  • Compound A: nephrotoxic in rats, NOT in humans; use FGF >2 L/min with soda lime
  • Emergence delirium in children - treat with analgesia, dexmedetomidine, propofol
  • QT prolongation - clinical significance uncertain
  • No halothane hepatitis - not metabolized to trifluoroacetate
  • Metabolized by CYP2E1 - 5%; induced by alcohol and phenobarbital
  • Malignant hyperthermia trigger - contraindicated in susceptible patients
  • Uterine relaxation at >1 MAC - relevant in obstetric practice
  • Desiccated CO2 absorbent → fire risk (circuit ignition) + CO production

Sources:
  • Morgan & Mikhail's Clinical Anesthesiology, 7e, pp. 312-314
  • Goodman & Gilman's Pharmacological Basis of Therapeutics, pp. 498-499
  • Miller's Anesthesia, 10e, blocks 6, 27, 29
  • Barash, Cullen & Stoelting's Clinical Anesthesia, 9e, pp. 1403-1404
  • Katzung's Basic & Clinical Pharmacology, 16e, Table 25-1
  • Lippincott Illustrated Reviews: Pharmacology - p. 677
Recent evidence note: A 2026 meta-analysis (PMID: 41217504) found EEG-guided sevoflurane dosing reduces emergence delirium in children compared to standard care. A 2025 meta-analysis (PMID: 41062401) suggests remimazolam has hemodynamic advantages over sevoflurane in select populations. These do not overturn current clinical practice recommendations.

Create a study guide PDF summarizing sevoflurane pharmacology for exam prep

Reading File
Running Command

ls -la /home/daytona/workspace/ 2>/dev/null && python3 -c "import reportlab; print('reportlab ok')" && python3 -c "from reportlab.lib.pagesizes import A4; print('A4 ok')"

Running Command

mkdir -p /home/daytona/workspace/sevoflurane-study-guide

Writing File

~/sevoflurane-study-guide/build_pdf.py

from reportlab.lib.pagesizes import A4
from reportlab.lib import colors
from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle
from reportlab.lib.units import cm, mm
from reportlab.platypus import (SimpleDocTemplate, Paragraph, Spacer, Table,
                                TableStyle, HRFlowable, KeepTogether, PageBreak)
from reportlab.lib.enums import TA_CENTER, TA_LEFT, TA_JUSTIFY
from reportlab.platypus import Image
from reportlab.graphics.shapes import Drawing, Rect, String, Line, Circle
from reportlab.graphics import renderPDF
import os

OUTPUT = "/home/daytona/workspace/sevoflurane-study-guide/Sevoflurane_Study_Guide.pdf"

# ── Colour Palette ────────────────────────────────────────────────────────────
NAVY    = colors.HexColor("#1A3A5C")
TEAL    = colors.HexColor("#0D7680")
AMBER   = colors.HexColor("#E07B00")
RED     = colors.HexColor("#C0392B")
GREEN   = colors.HexColor("#1A7A4A")
PURPLE  = colors.HexColor("#6A3D9A")
LIGHT   = colors.HexColor("#EAF4FB")
LIGHT2  = colors.HexColor("#FFF8EC")
LIGHT3  = colors.HexColor("#F0FFF4")
LIGHT4  = colors.HexColor("#FDF0F0")
LIGHT5  = colors.HexColor("#F5F0FF")
WHITE   = colors.white
DGREY   = colors.HexColor("#444444")
MGREY   = colors.HexColor("#888888")
LGREY   = colors.HexColor("#F5F5F5")
BORDER  = colors.HexColor("#CCDDEE")

doc = SimpleDocTemplate(
    OUTPUT,
    pagesize=A4,
    leftMargin=1.8*cm, rightMargin=1.8*cm,
    topMargin=2*cm, bottomMargin=2*cm,
    title="Sevoflurane – Anaesthesia Exam Study Guide",
    author="Orris Medical AI",
)

W, H = A4
CW = W - 3.6*cm   # content width

styles = getSampleStyleSheet()

def S(name, **kw):
    base = styles[name] if name in styles else styles["Normal"]
    return ParagraphStyle(name + str(id(kw)), parent=base, **kw)

# ── Custom Styles ─────────────────────────────────────────────────────────────
cover_title  = S("Title",    fontSize=30, textColor=WHITE,   leading=36, alignment=TA_CENTER, fontName="Helvetica-Bold")
cover_sub    = S("Normal",   fontSize=14, textColor=LIGHT,   leading=20, alignment=TA_CENTER, fontName="Helvetica")
cover_tag    = S("Normal",   fontSize=10, textColor=colors.HexColor("#AACCDD"), alignment=TA_CENTER)

sec_head     = S("Heading1", fontSize=13, textColor=WHITE,   leading=17, fontName="Helvetica-Bold", spaceAfter=2, spaceBefore=4)
sub_head     = S("Heading2", fontSize=10.5, textColor=NAVY,  leading=14, fontName="Helvetica-Bold", spaceBefore=6, spaceAfter=2)
body         = S("Normal",   fontSize=8.5, textColor=DGREY,  leading=13, alignment=TA_JUSTIFY)
body_small   = S("Normal",   fontSize=7.8, textColor=DGREY,  leading=11.5)
bullet_style = S("Normal",   fontSize=8.5, textColor=DGREY,  leading=13, leftIndent=14, firstLineIndent=-10)
bold_bullet  = S("Normal",   fontSize=8.5, textColor=NAVY,   leading=13, leftIndent=14, firstLineIndent=-10, fontName="Helvetica-Bold")
warn_text    = S("Normal",   fontSize=8.5, textColor=RED,    leading=13, fontName="Helvetica-Bold")
tip_text     = S("Normal",   fontSize=8.5, textColor=GREEN,  leading=13, fontName="Helvetica-BoldOblique")
table_hdr    = S("Normal",   fontSize=8,   textColor=WHITE,  leading=11, fontName="Helvetica-Bold", alignment=TA_CENTER)
table_cell   = S("Normal",   fontSize=8,   textColor=DGREY,  leading=11)
table_cell_c = S("Normal",   fontSize=8,   textColor=DGREY,  leading=11, alignment=TA_CENTER)
table_lbl    = S("Normal",   fontSize=8,   textColor=NAVY,   leading=11, fontName="Helvetica-Bold")
footnote     = S("Normal",   fontSize=7,   textColor=MGREY,  leading=10, fontName="Helvetica-Oblique")
highlight    = S("Normal",   fontSize=8.5, textColor=NAVY,   leading=13, fontName="Helvetica-Bold")
page_hdr     = S("Normal",   fontSize=7.5, textColor=MGREY,  leading=10, alignment=TA_CENTER)

story = []

# ══════════════════════════════════════════════════════════════════════════════
# HELPER: section banner
# ══════════════════════════════════════════════════════════════════════════════
def section_banner(number, title, color=NAVY):
    data = [[Paragraph(f"<b>{number}  &nbsp; {title}</b>", sec_head)]]
    t = Table(data, colWidths=[CW])
    t.setStyle(TableStyle([
        ("BACKGROUND", (0,0),(-1,-1), color),
        ("ROUNDEDCORNERS", [4]),
        ("TOPPADDING",   (0,0),(-1,-1), 5),
        ("BOTTOMPADDING",(0,0),(-1,-1), 5),
        ("LEFTPADDING",  (0,0),(-1,-1), 10),
        ("RIGHTPADDING", (0,0),(-1,-1), 8),
    ]))
    story.append(Spacer(1, 6))
    story.append(t)
    story.append(Spacer(1, 4))

def info_box(text, bg=LIGHT, border_color=TEAL, icon="ℹ"):
    data = [[Paragraph(f"<b>{icon}</b>"), Paragraph(text, body)]]
    t = Table(data, colWidths=[0.5*cm, CW-0.6*cm])
    t.setStyle(TableStyle([
        ("BACKGROUND",   (0,0),(-1,-1), bg),
        ("BOX",          (0,0),(-1,-1), 0.8, border_color),
        ("TOPPADDING",   (0,0),(-1,-1), 5),
        ("BOTTOMPADDING",(0,0),(-1,-1), 5),
        ("LEFTPADDING",  (0,0),(-1,-1), 6),
        ("VALIGN",       (0,0),(-1,-1), "TOP"),
    ]))
    story.append(t)
    story.append(Spacer(1, 4))

def bullet(text, bold=False):
    st = bold_bullet if bold else bullet_style
    story.append(Paragraph(f"• {text}", st))

def spacer(h=6):
    story.append(Spacer(1, h))

def hr():
    story.append(HRFlowable(width=CW, thickness=0.5, color=BORDER, spaceAfter=4, spaceBefore=4))

def two_col_table(rows, col1_w=None, col2_w=None, hdr=None, hdr_color=NAVY, stripe=True):
    if col1_w is None: col1_w = CW * 0.38
    if col2_w is None: col2_w = CW - col1_w
    data = []
    if hdr:
        data.append([Paragraph(hdr[0], table_hdr), Paragraph(hdr[1], table_hdr)])
    for i, (k, v) in enumerate(rows):
        data.append([Paragraph(k, table_lbl), Paragraph(v, table_cell)])
    t = Table(data, colWidths=[col1_w, col2_w])
    style_cmds = [
        ("TOPPADDING",   (0,0),(-1,-1), 4),
        ("BOTTOMPADDING",(0,0),(-1,-1), 4),
        ("LEFTPADDING",  (0,0),(-1,-1), 6),
        ("RIGHTPADDING", (0,0),(-1,-1), 6),
        ("VALIGN",       (0,0),(-1,-1), "TOP"),
        ("GRID",         (0,0),(-1,-1), 0.4, BORDER),
        ("ROWBACKGROUNDS", (0, 1 if hdr else 0), (-1,-1), [WHITE, LGREY] if stripe else [WHITE]),
    ]
    if hdr:
        style_cmds += [
            ("BACKGROUND", (0,0),(-1,0), hdr_color),
            ("TEXTCOLOR",  (0,0),(-1,0), WHITE),
        ]
    t.setStyle(TableStyle(style_cmds))
    story.append(t)
    story.append(Spacer(1,4))

def multi_col_table(headers, rows, col_widths=None, hdr_color=NAVY):
    n = len(headers)
    if col_widths is None:
        col_widths = [CW / n] * n
    data = [[Paragraph(h, table_hdr) for h in headers]]
    for row in rows:
        data.append([Paragraph(str(c), table_cell_c) for c in row])
    t = Table(data, colWidths=col_widths)
    t.setStyle(TableStyle([
        ("BACKGROUND",    (0,0),(-1,0), hdr_color),
        ("ROWBACKGROUNDS",(0,1),(-1,-1), [WHITE, LGREY]),
        ("GRID",          (0,0),(-1,-1), 0.4, BORDER),
        ("TOPPADDING",    (0,0),(-1,-1), 4),
        ("BOTTOMPADDING", (0,0),(-1,-1), 4),
        ("LEFTPADDING",   (0,0),(-1,-1), 4),
        ("RIGHTPADDING",  (0,0),(-1,-1), 4),
        ("VALIGN",        (0,0),(-1,-1), "MIDDLE"),
    ]))
    story.append(t)
    story.append(Spacer(1,4))

# ══════════════════════════════════════════════════════════════════════════════
#  COVER PAGE
# ══════════════════════════════════════════════════════════════════════════════
def cover_page():
    # Full-width blue background banner
    banner_data = [[
        Paragraph("SEVOFLURANE", cover_title),
    ]]
    banner = Table(banner_data, colWidths=[CW])
    banner.setStyle(TableStyle([
        ("BACKGROUND",   (0,0),(-1,-1), NAVY),
        ("TOPPADDING",   (0,0),(-1,-1), 28),
        ("BOTTOMPADDING",(0,0),(-1,-1), 6),
        ("LEFTPADDING",  (0,0),(-1,-1), 10),
        ("ROUNDEDCORNERS",[6]),
    ]))
    story.append(banner)

    subtitle_data = [[Paragraph("Complete Pharmacology Study Guide", cover_sub)]]
    subtitle_tbl = Table(subtitle_data, colWidths=[CW])
    subtitle_tbl.setStyle(TableStyle([
        ("BACKGROUND",   (0,0),(-1,-1), TEAL),
        ("TOPPADDING",   (0,0),(-1,-1), 8),
        ("BOTTOMPADDING",(0,0),(-1,-1), 14),
        ("ROUNDEDCORNERS",[0,0,6,6]),
    ]))
    story.append(subtitle_tbl)
    spacer(12)

    tag_data = [[Paragraph("For MD / DNB / FRCA Anaesthesia Examinations  •  Based on Miller's, Morgan &amp; Mikhail's, Goodman &amp; Gilman's, Barash &amp; Katzung", cover_tag)]]
    tag_tbl = Table(tag_data, colWidths=[CW])
    tag_tbl.setStyle(TableStyle([
        ("TOPPADDING",(0,0),(-1,-1),4), ("BOTTOMPADDING",(0,0),(-1,-1),4)
    ]))
    story.append(tag_tbl)
    spacer(10)

    # Quick-reference card on cover
    qr_rows = [
        ("MAC (adult, O₂)", "2.0%"),
        ("MAC awake", "~0.6%"),
        ("MAC (neonate/infant)", "~3.2–3.3%"),
        ("MAC (elderly >65 y)", "~1.5%"),
        ("Blood:gas coeff", "0.65"),
        ("Metabolism (CYP2E1)", "~5%"),
        ("Vaporizer type", "Standard variable-bypass"),
        ("Odour", "Sweet, non-pungent"),
        ("Flammable?", "No"),
    ]
    story.append(Paragraph("<b>Quick Reference Card</b>", sub_head))
    two_col_table(qr_rows, hdr=("PROPERTY", "VALUE"), hdr_color=TEAL)
    spacer(8)

    story.append(Paragraph(
        "<b>Indications at a glance:</b>  Inhalational induction (esp. paediatrics) • Maintenance of GA • Ambulatory surgery • "
        "Asthma / bronchospasm • Day-case surgery • Patients at risk for myocardial ischaemia",
        body))
    spacer(4)
    info_box(
        "<b>Contraindications:</b>  Malignant hyperthermia susceptibility  •  Severe hypovolaemia  •  Raised intracranial pressure",
        bg=LIGHT4, border_color=RED, icon="⚠")

cover_page()
story.append(PageBreak())

# ══════════════════════════════════════════════════════════════════════════════
# SECTION 1 – PHYSICAL & PHARMACOKINETIC PROPERTIES
# ══════════════════════════════════════════════════════════════════════════════
section_banner("01", "Physical & Pharmacokinetic Properties", NAVY)

story.append(Paragraph("<b>Chemical identity:</b>  Fluorinated methyl isopropyl ether — completely fluorinated, sweet-smelling, colourless volatile liquid at room temperature.", body))
spacer(4)

phys_rows = [
    ("Chemical class",         "Fluorinated methyl isopropyl ether"),
    ("Molecular weight",       "200.05 g/mol"),
    ("Boiling point",          "58.5°C"),
    ("Vapour pressure (20°C)", "157 mmHg"),
    ("Vaporizer",              "Standard variable-bypass (no heated vaporizer needed)"),
    ("Flammable / explosive",  "No (in air or O₂)"),
    ("Storage",                "Sealed amber bottle, no preservative required"),
    ("Stability",              "Unstable in desiccated soda lime → Compound A + CO"),
]
story.append(Paragraph("<b>Physical Properties</b>", sub_head))
two_col_table(phys_rows)

pk_rows = [
    ("Blood:gas partition coeff",   "0.65  (rapid induction/emergence)"),
    ("Brain:blood partition coeff", "1.7"),
    ("Oil:gas partition coeff",     "~47–53"),
    ("MAC (adult, 100% O₂)",        "2.0%  (range 1.71–2.05%)"),
    ("MAC awake",                   "~0.6%"),
    ("MAC – neonates",              "~3.3%"),
    ("MAC – infants (peak ~6 mo)",  "~3.2%"),
    ("MAC – elderly (>65 yr)",      "~1.5%"),
    ("Induction concentration",     "2–4% (maintenance); 4–8% (rapid mask induction)"),
    ("Time to loss of consciousness","1–2 min (inhalational)"),
    ("Metabolism",                  "~5% via hepatic CYP2E1"),
    ("Key metabolites",             "Hexafluoroisopropanol (HFIP) + inorganic fluoride (F⁻)"),
    ("Peak serum F⁻",               "22–31 µmol/L (>50 µmol/L in ~7% — no clinical nephrotoxicity)"),
    ("Excretion",                   "Predominantly exhaled unchanged via lungs"),
]
story.append(Paragraph("<b>Pharmacokinetic Parameters</b>", sub_head))
two_col_table(pk_rows)

info_box(
    "<b>Low blood:gas solubility (0.65)</b> = quick equilibration between alveoli and blood → fast induction, rapid changes in depth, "
    "and brisk emergence. Faster than isoflurane; slightly slower than desflurane.",
    bg=LIGHT, border_color=TEAL)

# MAC Modifiers
story.append(Paragraph("<b>MAC Modifiers</b>", sub_head))
mac_data = [
    ["Decrease MAC", "Increase MAC"],
    ["Increasing age", "Infancy (peak ~6 months)"],
    ["Hypothermia", "Hyperthermia"],
    ["Hypotension (MAP <50 mmHg)", "Chronic alcohol use"],
    ["Pregnancy", "Chronic opioid use"],
    ["Opioids (additive)", "Hyperthyroidism"],
    ["N₂O (additive)", "CNS stimulants"],
    ["Alpha-2 agonists (dexmedetomidine)", "—"],
    ["Benzodiazepines", "—"],
    ["Metabolic acidosis / hypoxia", "—"],
]
mac_t = Table(mac_data, colWidths=[CW/2, CW/2])
mac_t.setStyle(TableStyle([
    ("BACKGROUND",   (0,0),(0,0), RED),
    ("BACKGROUND",   (1,0),(1,0), GREEN),
    ("TEXTCOLOR",    (0,0),(-1,0), WHITE),
    ("FONTNAME",     (0,0),(-1,0), "Helvetica-Bold"),
    ("FONTSIZE",     (0,0),(-1,-1), 8),
    ("ROWBACKGROUNDS",(0,1),(-1,-1), [WHITE, LGREY]),
    ("GRID",         (0,0),(-1,-1), 0.4, BORDER),
    ("TOPPADDING",   (0,0),(-1,-1), 3),
    ("BOTTOMPADDING",(0,0),(-1,-1), 3),
    ("LEFTPADDING",  (0,0),(-1,-1), 6),
    ("VALIGN",       (0,0),(-1,-1), "MIDDLE"),
    ("ALIGN",        (0,0),(-1,0), "CENTER"),
]))
story.append(mac_t)
spacer(6)

story.append(PageBreak())

# ══════════════════════════════════════════════════════════════════════════════
# SECTION 2 – MECHANISM OF ACTION
# ══════════════════════════════════════════════════════════════════════════════
section_banner("02", "Mechanism of Action", TEAL)

moa_rows = [
    ("GABA-A receptor potentiation",  "Main mechanism — enhances inhibitory Cl⁻ conductance → CNS depression"),
    ("NMDA receptor inhibition",      "Reduces excitatory glutamate signalling → amnesia, immobility"),
    ("2-pore domain K⁺ channels",     "TREK/TASK channel activation → neuronal hyperpolarisation"),
    ("Voltage-gated Na⁺/Ca²⁺ block",  "Reduces action potential generation and propagation"),
    ("Shaker-family Kv1.2 channels",  "Photoaffinity labelling confirms direct interaction"),
]
two_col_table(moa_rows, hdr=("TARGET", "EFFECT"), hdr_color=TEAL, col1_w=CW*0.34)

info_box("Sevoflurane does NOT have a single receptor target — it acts on multiple ion channels and receptors, a property shared by all volatile anaesthetics ('unitary theory').",
         bg=LIGHT, border_color=TEAL)

# ══════════════════════════════════════════════════════════════════════════════
# SECTION 3 – EFFECTS ON ORGAN SYSTEMS
# ══════════════════════════════════════════════════════════════════════════════
section_banner("03", "Effects on Organ Systems", NAVY)

# --- CVS ---
story.append(Paragraph("A.  Cardiovascular System", sub_head))
cvs = [
    ("BP",                     "Concentration-dependent ↓ (SVR reduction + mild myocardial depression)"),
    ("Heart rate",             "No significant tachycardia (contrast: isoflurane/desflurane which increase HR)"),
    ("Cardiac output",         "Mild ↓ — less well maintained than with isoflurane (no reflex tachycardia)"),
    ("SVR",                    "↓ — less pronounced than isoflurane or desflurane"),
    ("QT interval",            "Prolongation; may persist 60 min post-emergence in infants"),
    ("Arrhythmias",            "Does NOT sensitise myocardium to catecholamines (safe to use adrenaline)"),
    ("Coronary vasodilation",  "Half as potent as isoflurane — less 'coronary steal' risk"),
    ("Ischaemic preconditioning","Cardioprotective — reduces ischaemia–reperfusion injury"),
]
two_col_table(cvs, col1_w=CW*0.30)

# --- Respiratory ---
story.append(Paragraph("B.  Respiratory System", sub_head))
resp = [
    ("Tidal volume",       "↓ (concentration-dependent)"),
    ("Respiratory rate",   "↑ (but does not compensate for ↓ Vt)"),
    ("Minute ventilation", "↓ net → ↑ PaCO₂"),
    ("Airway irritation",  "None — ideal for mask induction (no cough, no laryngospasm)"),
    ("Bronchodilation",    "MOST POTENT bronchodilator of all inhaled anaesthetics"),
    ("Secretions",         "No significant increase"),
    ("HPV",                "↓ Hypoxic pulmonary vasoconstriction → can worsen V/Q mismatch"),
]
two_col_table(resp, col1_w=CW*0.30)
info_box("KEY EXAM POINT: Sevoflurane is the <b>most effective clinical bronchodilator</b> among all inhalational anaesthetics — drug of choice for patients with reactive airways / status asthmaticus.",
         bg=LIGHT3, border_color=GREEN, icon="★")

# --- CNS ---
story.append(Paragraph("C.  Central Nervous System", sub_head))
cns = [
    ("CMRO₂",            "↓ (dose-dependent cerebral metabolic depression)"),
    ("CBF / ICP",        "↑ CVD → mild ↑ CBF and ICP at normocarbia (>1.5 MAC more marked)"),
    ("Autoregulation",   "Impaired at >1.5 MAC"),
    ("CO₂ reactivity",   "Preserved — hyperventilation counteracts ICP rise"),
    ("Seizures",         "NOT epileptogenic (unlike enflurane); spike-wave at >2 MAC rare"),
    ("Emergence delirium","Common in children — short-lived, no long-term sequelae"),
    ("EEG",              "Burst suppression at high concentrations"),
]
two_col_table(cns, col1_w=CW*0.30)

spacer(4)
info_box("CAUTION in raised ICP: Use hyperventilation to maintain normocarbia and counteract cerebrovascular dilation. Limit concentration, especially >1.5 MAC.",
         bg=LIGHT4, border_color=RED, icon="⚠")

# --- NMJ ---
story.append(Paragraph("D.  Neuromuscular System", sub_head))
bullet("Potentiates non-depolarising NMBAs (vecuronium, rocuronium, atracurium) — reduce NMBA dose by ~30–40%")
bullet("Adequate muscle relaxation for intubation at high concentrations after inhalational induction")
bullet("<b>Trigger for Malignant Hyperthermia (MH)</b> — ABSOLUTE CONTRAINDICATION in susceptible patients", bold=True)
spacer(4)

# --- Renal ---
story.append(Paragraph("E.  Renal System", sub_head))
renal = [
    ("Direct effect",          "Slight ↓ renal blood flow"),
    ("Compound A",             "Nephrotoxic in rats (proximal tubular necrosis >150 ppm-hr); NOT clinically nephrotoxic in humans"),
    ("Mechanism (rats)",       "CYP2E1 / β-lyase pathway → reactive thionoacyl fluoride → tubular injury"),
    ("Why safe in humans",     "Human kidneys have far lower β-lyase activity than rat kidneys"),
    ("Serum fluoride (F⁻)",    "Peak 22–31 µmol/L; >50 µmol/L in ~7% — no clinical renal dysfunction"),
    ("Compound A production",  "↑ with desiccated Baralyme, low FGF, high concentration, long duration"),
    ("FDA recommendation",     "FGF ≥1–2 L/min; limit to ≤2 MAC-hours at low flow"),
]
two_col_table(renal, col1_w=CW*0.30)

# --- Hepatic ---
story.append(Paragraph("F.  Hepatic System", sub_head))
hep = [
    ("Portal vein flow",      "↓ (dose-dependent)"),
    ("Hepatic artery flow",   "↑ (compensatory) — total hepatic O₂ delivery maintained"),
    ("Hepatotoxicity",        "Not reported — NOT metabolised to trifluoroacetate"),
    ("Mechanism of safety",   "Metabolised to HFIP + glucuronide, NOT acyl halide that stimulates antibodies"),
]
two_col_table(hep, col1_w=CW*0.30)
info_box("No halothane-type hepatitis with sevoflurane — CYP2E1 pathway produces hexafluoroisopropanol (HFIP), not trifluoroacetate. No immune-mediated hepatotoxicity.",
         bg=LIGHT3, border_color=GREEN)

# --- Uterus ---
story.append(Paragraph("G.  Uterus / Obstetrics", sub_head))
bullet("Dose-dependent uterine relaxation (tocolytic effect)")
bullet("At >1 MAC: may increase uterine bleeding during Caesarean section")
bullet("Crosses placenta — safe in low doses for maternal anaesthesia")
bullet("Use ≤1 MAC for obstetric procedures to minimise uterine atony")
spacer(4)

story.append(PageBreak())

# ══════════════════════════════════════════════════════════════════════════════
# SECTION 4 – INDICATIONS
# ══════════════════════════════════════════════════════════════════════════════
section_banner("04", "Indications", GREEN)

indications = [
    ("1", "Inhalational induction of anaesthesia",    "Esp. children & needle-phobic adults — non-pungent, non-irritating"),
    ("2", "Maintenance of general anaesthesia",       "After IV or inhalational induction; 1–3% in O₂ or O₂/N₂O"),
    ("3", "Ambulatory / day-case surgery",            "Rapid emergence → early discharge"),
    ("4", "Paediatric anaesthesia",                   "Drug of choice — replaces halothane globally"),
    ("5", "Reactive airways / asthma",               "Most potent bronchodilator; reduces bronchospasm"),
    ("6", "IHD / tachyarrhythmia risk",              "No reflex tachycardia, no arrhythmia sensitisation"),
    ("7", "VIMA (volatile induction + maintenance)", "Single-agent technique; earlier orientation vs isoflurane"),
    ("8", "Rapid sequence inhalational induction",   "4–8% with 50% N₂O → unconsciousness in <1 min"),
]
ind_data = [[Paragraph("#", table_hdr), Paragraph("Indication", table_hdr), Paragraph("Notes", table_hdr)]] + [
    [Paragraph(r[0], table_cell_c), Paragraph(r[1], table_lbl), Paragraph(r[2], table_cell)]
    for r in indications
]
ind_t = Table(ind_data, colWidths=[0.5*cm, CW*0.38, CW*0.57])
ind_t.setStyle(TableStyle([
    ("BACKGROUND",   (0,0),(-1,0), GREEN),
    ("TEXTCOLOR",    (0,0),(-1,0), WHITE),
    ("ROWBACKGROUNDS",(0,1),(-1,-1),[WHITE, LGREY]),
    ("GRID",         (0,0),(-1,-1), 0.4, BORDER),
    ("TOPPADDING",   (0,0),(-1,-1), 4),
    ("BOTTOMPADDING",(0,0),(-1,-1), 4),
    ("LEFTPADDING",  (0,0),(-1,-1), 5),
    ("VALIGN",       (0,0),(-1,-1), "TOP"),
]))
story.append(ind_t)
spacer(6)

# ══════════════════════════════════════════════════════════════════════════════
# SECTION 5 – CONTRAINDICATIONS
# ══════════════════════════════════════════════════════════════════════════════
section_banner("05", "Contraindications", RED)

ci = [
    ("Malignant Hyperthermia susceptibility",
     "ABSOLUTE — Sevoflurane is a potent MH trigger; causes uncontrolled Ca²⁺ release via mutant RyR1 receptor. "
     "Prepare vapour-free machine (flush 10–20 min with high O₂ flow). Have dantrolene ready."),
    ("Severe hypovolaemia / haemodynamic instability",
     "Further ↓ SVR and BP → risk of cardiovascular collapse."),
    ("Raised intracranial pressure",
     "Cerebral vasodilation ↑ ICP — use only if adequate hyperventilation maintained; avoid in decompensated head injury."),
    ("Desiccated CO₂ absorbent in circuit",
     "Risk of fire, explosion, and CO production — check absorbent moisture before use."),
]
ci_data = [[Paragraph("Contraindication", table_hdr), Paragraph("Reason / Action", table_hdr)]] + [
    [Paragraph(r[0], table_lbl), Paragraph(r[1], table_cell)] for r in ci
]
ci_t = Table(ci_data, colWidths=[CW*0.32, CW*0.68])
ci_t.setStyle(TableStyle([
    ("BACKGROUND",   (0,0),(-1,0), RED),
    ("TEXTCOLOR",    (0,0),(-1,0), WHITE),
    ("ROWBACKGROUNDS",(0,1),(-1,-1),[LIGHT4, WHITE]),
    ("GRID",         (0,0),(-1,-1), 0.4, BORDER),
    ("TOPPADDING",   (0,0),(-1,-1), 5),
    ("BOTTOMPADDING",(0,0),(-1,-1), 5),
    ("LEFTPADDING",  (0,0),(-1,-1), 6),
    ("VALIGN",       (0,0),(-1,-1), "TOP"),
]))
story.append(ci_t)
spacer(6)

# ══════════════════════════════════════════════════════════════════════════════
# SECTION 6 – PRECAUTIONS & CARE
# ══════════════════════════════════════════════════════════════════════════════
section_banner("06", "Precautions & Care to be Taken", AMBER)

prec_areas = [
    ("Malignant Hyperthermia", LIGHT4, RED, [
        "Wash out anaesthesia machine: flush with O₂ at 10 L/min for 10–20 min before use",
        "Replace breathing circuit, reservoir bag, and CO₂ canister",
        "Have dantrolene available (2.5 mg/kg IV bolus; repeat up to 10 mg/kg)",
        "Use TIVA (propofol + remifentanil) for MH-susceptible patients",
        "Monitor temperature, EtCO₂, and muscle rigidity vigilantly",
    ]),
    ("CO₂ Absorbent / Compound A / Fire Risk", LIGHT2, AMBER, [
        "Never use with desiccated soda lime or Baralyme — risk of fire and Compound A",
        "Prefer calcium hydroxide-based absorbents (Amsorb®, Dragersorb Free®) — minimal Compound A",
        "Maintain FGF ≥2 L/min for prolonged (>2–3 hr) anaesthesia",
        "Do not run dry O₂/N₂O flow through circuit overnight",
        "Isolated circuit fires reported with desiccated absorbent — inspect moisture before use",
    ]),
    ("Paediatric – Emergence Delirium", LIGHT5, PURPLE, [
        "Warn parents — not associated with long-term harm",
        "Prevention: adequate analgesia is the most important measure",
        "Pharmacological prevention: fentanyl 1 µg/kg IV, OR dexmedetomidine 0.3–0.5 µg/kg, OR propofol 1 mg/kg at end of case",
        "Midazolam premedication alone is NOT effective for emergence delirium",
        "EEG-guided dosing may reduce incidence (2026 meta-analysis, PMID 41217504)",
    ]),
    ("Obstetric Surgery", LIGHT, TEAL, [
        "Keep ≤1 MAC to minimise uterine atony and excessive blood loss",
        "Have oxytocin ready and increase dose if uterine tone is poor",
        "For GA Caesarean: use 0.5 MAC sevoflurane + 50% N₂O until delivery, then titrate",
    ]),
    ("QT Prolongation", LIGHT4, RED, [
        "Caution in patients on drugs that prolong QT: Class Ia/III antiarrhythmics, TCAs, haloperidol",
        "Monitor ECG in high-risk patients; prolongation may persist up to 60 min post-emergence in infants",
        "Correct electrolyte abnormalities (K⁺, Mg²⁺) pre-operatively",
    ]),
    ("Renal Impairment", LIGHT2, AMBER, [
        "Clinically, sevoflurane nephrotoxicity is NOT established in humans",
        "Caution in severe CKD: use FGF ≥2 L/min, avoid prolonged low-flow anaesthesia",
        "Monitor creatinine / urea post-operatively after prolonged exposure",
    ]),
]

for title, bg, border, bullets in prec_areas:
    header_data = [[Paragraph(f"<b>{title}</b>",
                              S("Normal", fontSize=9, textColor=border, fontName="Helvetica-Bold", leading=13))]]
    ht = Table(header_data, colWidths=[CW])
    ht.setStyle(TableStyle([
        ("BACKGROUND",   (0,0),(-1,-1), bg),
        ("LEFTPADDING",  (0,0),(-1,-1), 8),
        ("TOPPADDING",   (0,0),(-1,-1), 4),
        ("BOTTOMPADDING",(0,0),(-1,-1), 2),
        ("LINEBELOW",    (0,0),(-1,-1), 1, border),
    ]))
    story.append(ht)
    for b in bullets:
        bullet_data = [[Paragraph("•", body), Paragraph(b, body)]]
        bt = Table(bullet_data, colWidths=[0.4*cm, CW-0.4*cm])
        bt.setStyle(TableStyle([
            ("BACKGROUND",   (0,0),(-1,-1), bg),
            ("TOPPADDING",   (0,0),(-1,-1), 2),
            ("BOTTOMPADDING",(0,0),(-1,-1), 2),
            ("LEFTPADDING",  (0,0),(-1,-1), 8),
            ("VALIGN",       (0,0),(-1,-1), "TOP"),
        ]))
        story.append(bt)
    story.append(Spacer(1, 5))

story.append(PageBreak())

# ══════════════════════════════════════════════════════════════════════════════
# SECTION 7 – DRUG INTERACTIONS
# ══════════════════════════════════════════════════════════════════════════════
section_banner("07", "Drug Interactions", PURPLE)

di_rows = [
    ("Non-depolarising NMBAs\n(vec, roc, atrac, cis-atrac)",
     "POTENTIATED — ↑ block duration and depth; reduce NMBA dose by ~30–40%", "Significant"),
    ("Nitrous oxide (N₂O)",
     "ADDITIVE MAC reduction — can use 1–1.5% sevo with 50–60% N₂O", "Beneficial"),
    ("Opioids",
     "Reduce MAC (supradditive); ↑ PONV risk", "Dose-adjust"),
    ("Epinephrine (adrenaline)",
     "SAFE — does NOT sensitise myocardium to arrhythmias (unlike halothane)", "Safe"),
    ("Beta-blockers / antihypertensives",
     "Additive hypotension; anticipate exaggerated BP drop", "Caution"),
    ("QT-prolonging drugs\n(Class Ia/III, TCAs, haloperidol)",
     "Additive QT prolongation — risk of torsades de pointes", "Caution"),
    ("CYP2E1 inducers\n(ethanol, isoniazid, phenobarbital)",
     "↑ Metabolism → ↑ serum fluoride production", "Caution"),
    ("Alpha-2 agonists\n(dexmedetomidine, clonidine)",
     "↓ MAC significantly (20–40%) — useful for emergence delirium prevention", "Beneficial"),
    ("Propofol",
     "Often combined for TIVA/inhalational technique — no adverse interaction", "Compatible"),
]
di_data = [[Paragraph(h, table_hdr) for h in ["Drug / Class", "Interaction", "Clinical Significance"]]]
sig_colors = {"Significant": colors.HexColor("#FFE0DC"), "Beneficial": LIGHT3,
              "Dose-adjust": LIGHT2, "Caution": LIGHT2, "Safe": LIGHT3, "Compatible": LIGHT}
for r in di_rows:
    di_data.append([
        Paragraph(r[0], table_lbl),
        Paragraph(r[1], table_cell),
        Paragraph(r[2], table_cell_c),
    ])
di_t = Table(di_data, colWidths=[CW*0.26, CW*0.55, CW*0.19])
di_cmds = [
    ("BACKGROUND",    (0,0),(-1,0), PURPLE),
    ("TEXTCOLOR",     (0,0),(-1,0), WHITE),
    ("GRID",          (0,0),(-1,-1), 0.4, BORDER),
    ("TOPPADDING",    (0,0),(-1,-1), 4),
    ("BOTTOMPADDING", (0,0),(-1,-1), 4),
    ("LEFTPADDING",   (0,0),(-1,-1), 5),
    ("VALIGN",        (0,0),(-1,-1), "TOP"),
    ("ROWBACKGROUNDS",(0,1),(-1,-1),[WHITE, LGREY]),
]
di_t.setStyle(TableStyle(di_cmds))
story.append(di_t)
spacer(6)

# ══════════════════════════════════════════════════════════════════════════════
# SECTION 8 – COMPARISON TABLE
# ══════════════════════════════════════════════════════════════════════════════
section_banner("08", "Volatile Anaesthetic Comparison", TEAL)

comp_headers = ["Property", "Sevoflurane", "Isoflurane", "Desflurane", "Halothane"]
comp_rows = [
    ["Blood:gas coeff",       "0.65",     "1.40",      "0.42",   "2.30"],
    ["MAC (%)",               "2.0",      "1.15",      "6–7",    "0.75"],
    ["Vaporizer",             "Standard", "Standard",  "Heated", "Standard"],
    ["Inhalational induction","Excellent","Poor (pungent)","Poor (pungent)","Good"],
    ["Metabolism",            "~5%",      "<2%",       "<0.05%", ">40%"],
    ["Hepatotoxicity",        "No",       "Rare",      "No",     "Yes (hepatitis)"],
    ["Arrhythmia sensitisation","No",     "Minimal",   "No",     "YES"],
    ["Bronchodilation",       "BEST",     "Good",      "Good",   "Good"],
    ["Heart rate effect",     "None",     "↑ HR",      "↑↑ HR",  "↓ HR"],
    ["Compound A",            "Yes",      "No",        "No",     "No"],
    ["MH trigger",            "Yes",      "Yes",       "Yes",    "Yes"],
    ["PONV risk",             "Moderate", "Moderate",  "Lower",  "High"],
]
c_widths = [CW*0.22, CW*0.195, CW*0.195, CW*0.195, CW*0.195]
c_data = [[Paragraph(h, table_hdr) for h in comp_headers]]
for row in comp_rows:
    c_data.append([Paragraph(str(c), table_cell_c) for c in row])
# highlight sevoflurane column
c_t = Table(c_data, colWidths=c_widths)
sevo_col_style = [
    ("BACKGROUND",   (1,1),(1,-1), LIGHT),
    ("FONTNAME",     (1,1),(1,-1), "Helvetica-Bold"),
    ("TEXTCOLOR",    (1,1),(1,-1), NAVY),
]
c_t.setStyle(TableStyle([
    ("BACKGROUND",    (0,0),(-1,0), TEAL),
    ("TEXTCOLOR",     (0,0),(-1,0), WHITE),
    ("ROWBACKGROUNDS",(0,1),(-1,-1),[WHITE, LGREY]),
    ("GRID",          (0,0),(-1,-1), 0.4, BORDER),
    ("TOPPADDING",    (0,0),(-1,-1), 4),
    ("BOTTOMPADDING", (0,0),(-1,-1), 4),
    ("LEFTPADDING",   (0,0),(-1,-1), 4),
    ("VALIGN",        (0,0),(-1,-1), "MIDDLE"),
] + sevo_col_style))
story.append(c_t)
spacer(4)

story.append(PageBreak())

# ══════════════════════════════════════════════════════════════════════════════
# SECTION 9 – COMPOUND A & BIOTRANSFORMATION DETAIL
# ══════════════════════════════════════════════════════════════════════════════
section_banner("09", "Biotransformation & Toxicity (Compound A)", AMBER)

story.append(Paragraph("<b>Hepatic Metabolism (CYP2E1)</b>", sub_head))
met_rows = [
    ("Enzyme",         "CYP2E1 (hepatic microsomal)"),
    ("Rate",           "~5% of absorbed sevoflurane (10–25× isoflurane; ¼ of halothane)"),
    ("Inducers",       "Ethanol, isoniazid, phenobarbital → ↑ F⁻ production"),
    ("Main metabolite","Hexafluoroisopropanol (HFIP) → conjugated to glucuronide → excreted in urine"),
    ("By-product",     "Inorganic fluoride (F⁻) — peak 22–31 µmol/L; no renal concentrating defect"),
    ("No trifluoroacetate","Means NO immune-mediated hepatitis (unlike halothane)"),
]
two_col_table(met_rows)

story.append(Paragraph("<b>Compound A Formation</b>", sub_head))
story.append(Paragraph(
    "Sevoflurane reacts with <b>desiccated CO₂ absorbents</b> (soda lime, Baralyme) — strong bases (NaOH, KOH) extract a proton "
    "from the isopropyl group → forms <b>fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (Compound A)</b>.",
    body))
spacer(4)

ca_rows = [
    ("What increases Compound A", "Desiccated absorbent (Baralyme > soda lime) • Low FGF • High concentration • Long duration • High temperature"),
    ("Rat nephrotoxicity threshold","Proximal tubular necrosis at >150 ppm-hours; lethal at >1000 ppm-hours"),
    ("Human data",                 "NO clinically significant nephrotoxicity at any studied dose — large RCTs confirm safety"),
    ("Why rats ≠ humans",          "Human kidneys have far lower renal β-lyase activity → no reactive thionoacyl fluoride intermediate formed"),
    ("Peak Compound A with soda lime","~20 ppm at 1 L/min FGF"),
    ("With Baralyme",              "~30 ppm at 1 L/min FGF"),
    ("Safe absorbers",             "Amsorb® / Dragersorb Free® (calcium hydroxide only) — minimal Compound A"),
    ("FDA guidance",               "FGF ≥1–2 L/min; limit ≤2 MAC-hours with low FGF"),
    ("Circuit fire risk",          "Desiccated absorbent + sevoflurane → exothermic reaction → fire / CO production"),
]
two_col_table(ca_rows, col1_w=CW*0.34)

info_box(
    "<b>Bottom line for exams:</b>  Compound A is nephrotoxic in rats, but has NO proven clinical nephrotoxicity in humans. "
    "The clinically relevant precaution is to use FGF ≥2 L/min with soda lime, and to use calcium hydroxide absorbers when available.",
    bg=LIGHT2, border_color=AMBER, icon="📝")

# ══════════════════════════════════════════════════════════════════════════════
# SECTION 10 – HIGH-YIELD EXAM POINTS
# ══════════════════════════════════════════════════════════════════════════════
section_banner("10", "High-Yield Exam Points  ★", RED)

story.append(Paragraph("The following facts are most commonly tested in MD / DNB / FRCA examinations:", body))
spacer(4)

hye = [
    ("Non-pungent odour",          "→ Preferred for inhalational induction (paediatrics and adults); replaced halothane globally"),
    ("Most potent bronchodilator", "→ Best inhalational agent for reactive airways / status asthmaticus"),
    ("No tachycardia",             "→ Preferred in IHD, tachyarrhythmia-prone patients"),
    ("No catecholamine sensitisation","→ Safe to use with adrenaline infiltration (unlike halothane)"),
    ("QT prolongation",            "→ Can occur; may persist 60 min post-emergence in infants; caution with QT-prolonging drugs"),
    ("No halothane hepatitis",     "→ Metabolised to HFIP not trifluoroacetate → no antibody-mediated liver damage"),
    ("CYP2E1 metabolism",          "→ 5%; induced by ethanol, isoniazid, phenobarbital"),
    ("Compound A",                 "→ Nephrotoxic in rats NOT in humans; use FGF ≥2 L/min with soda lime"),
    ("Desiccated absorbent = fire","→ Circuit fire risk; also produces CO — always check absorbent before use"),
    ("Emergence delirium",         "→ Common in children; prevent with analgesia + dexmedetomidine / fentanyl / propofol"),
    ("Uterine relaxation at >1 MAC","→ Risk of PPH at Caesarean; use ≤1 MAC intra-operatively"),
    ("MH trigger",                 "→ Absolute contraindication in MH-susceptible patients; use TIVA instead"),
    ("Blood:gas coeff 0.65",       "→ Low = fast induction, rapid depth changes, quick emergence"),
    ("MAC 2.0%",                   "→ Less potent than isoflurane (1.15%) but more potent than desflurane (6–7%)"),
    ("N₂O additive",               "→ Co-administration allows ↓ sevoflurane concentration — reduces haemodynamic side effects"),
    ("NMBAs potentiated",          "→ Reduce dose of non-depolarising agents by ~30–40%"),
    ("ICP concern",                "→ Cerebrovascular dilation at normocarbia — counteracted by hyperventilation (CO₂ reactivity preserved)"),
]
hye_data = [[Paragraph(h, table_hdr) for h in ["Feature", "Exam-Ready Explanation"]]]
for r in hye:
    hye_data.append([Paragraph(r[0], table_lbl), Paragraph(r[1], table_cell)])
hye_t = Table(hye_data, colWidths=[CW*0.30, CW*0.70])
hye_t.setStyle(TableStyle([
    ("BACKGROUND",    (0,0),(-1,0), RED),
    ("TEXTCOLOR",     (0,0),(-1,0), WHITE),
    ("ROWBACKGROUNDS",(0,1),(-1,-1),[WHITE, LIGHT4]),
    ("GRID",          (0,0),(-1,-1), 0.4, BORDER),
    ("TOPPADDING",    (0,0),(-1,-1), 4),
    ("BOTTOMPADDING", (0,0),(-1,-1), 4),
    ("LEFTPADDING",   (0,0),(-1,-1), 6),
    ("VALIGN",        (0,0),(-1,-1), "TOP"),
]))
story.append(hye_t)
spacer(6)

# ══════════════════════════════════════════════════════════════════════════════
# SECTION 11 – CLINICAL DOSING QUICK CARD
# ══════════════════════════════════════════════════════════════════════════════
section_banner("11", "Clinical Dosing Quick Card", NAVY)

dose_rows = [
    ["Indication", "Concentration", "Notes"],
    ["Adult inhalational induction",     "4–8% (with 50–60% N₂O/O₂)", "Unconsciousness in ~1 min"],
    ["Paediatric mask induction",        "6–8%",                        "Reduce as sleep achieved"],
    ["Maintenance of anaesthesia",       "1–3% (in O₂ or O₂/N₂O)",    "Titrate to clinical effect"],
    ["Maintenance with N₂O",            "0.5–1.5%",                    "N₂O reduces MAC requirement"],
    ["Ambulatory / day-case",           "0.8–2%",                      "Reduce 15–20 min before end"],
    ["Obstetric GA (pre-delivery)",     "0.5 MAC sevo + 50% N₂O",      "Increase after cord clamping"],
    ["Status asthmaticus (ICU)",        "0.5–1.5%",                    "Via anaesthetic machine / AnaConDa"],
]
dose_t = Table(dose_rows, colWidths=[CW*0.33, CW*0.33, CW*0.34])
dose_t.setStyle(TableStyle([
    ("BACKGROUND",    (0,0),(-1,0), NAVY),
    ("TEXTCOLOR",     (0,0),(-1,0), WHITE),
    ("FONTNAME",      (0,0),(-1,0), "Helvetica-Bold"),
    ("FONTSIZE",      (0,0),(-1,-1), 8),
    ("ROWBACKGROUNDS",(0,1),(-1,-1),[WHITE, LIGHT]),
    ("GRID",          (0,0),(-1,-1), 0.4, BORDER),
    ("TOPPADDING",    (0,0),(-1,-1), 4),
    ("BOTTOMPADDING", (0,0),(-1,-1), 4),
    ("LEFTPADDING",   (0,0),(-1,-1), 6),
    ("VALIGN",        (0,0),(-1,-1), "MIDDLE"),
]))
story.append(dose_t)
spacer(8)

# Sources
story.append(Paragraph("<b>References</b>", sub_head))
refs = [
    "Miller's Anesthesia, 10th Edition (2024) — Blocks 6, 27, 29",
    "Morgan & Mikhail's Clinical Anesthesiology, 7th Edition — pp. 311–315",
    "Goodman & Gilman's Pharmacological Basis of Therapeutics — pp. 497–499",
    "Barash, Cullen & Stoelting's Clinical Anesthesia, 9th Edition — pp. 1403–1404",
    "Katzung's Basic & Clinical Pharmacology, 16th Edition — Table 25-1",
    "Lippincott Illustrated Reviews: Pharmacology — p. 677",
    "Javed J, et al. EEG-guided sevoflurane anesthesia vs. standard care in pediatric emergence delirium. J Anesth. 2026. [PMID: 41217504]",
]
for r in refs:
    story.append(Paragraph(f"• {r}", footnote))
    story.append(Spacer(1,2))

# ── BUILD ──────────────────────────────────────────────────────────────────────
def on_page(canvas, doc):
    canvas.saveState()
    # Header line
    canvas.setStrokeColor(BORDER)
    canvas.setLineWidth(0.5)
    canvas.line(1.8*cm, H - 1.4*cm, W - 1.8*cm, H - 1.4*cm)
    canvas.setFont("Helvetica", 7)
    canvas.setFillColor(MGREY)
    canvas.drawString(1.8*cm, H - 1.2*cm, "SEVOFLURANE — Anaesthesia Exam Study Guide")
    canvas.drawRightString(W - 1.8*cm, H - 1.2*cm, f"Page {doc.page}")
    # Footer
    canvas.line(1.8*cm, 1.5*cm, W - 1.8*cm, 1.5*cm)
    canvas.drawCentredString(W/2, 1.0*cm, "For educational purposes | Based on Miller's, Morgan & Mikhail's, Goodman & Gilman's, Barash, Katzung")
    canvas.restoreState()

doc.build(story, onFirstPage=on_page, onLaterPages=on_page)
print(f"PDF created: {OUTPUT}")
Running Command

cd /home/daytona/workspace/sevoflurane-study-guide && python3 build_pdf.py 2>&1

The error is a negative width issue in one of the tables. It's the info_box with a 0.5cm icon column — let me fix those thin column widths and also the precaution section table widths.
Editing File

~/sevoflurane-study-guide/build_pdf.py

Successfully replaced 1 instance(s) of the string in '/home/daytona/workspace/sevoflurane-study-guide/build_pdf.py'
Also fix the bullet sub-table in precautions section which has a 0.4cm column:
Editing File

~/sevoflurane-study-guide/build_pdf.py

Successfully replaced 1 instance(s) of the string in '/home/daytona/workspace/sevoflurane-study-guide/build_pdf.py'
Running Command

cd /home/daytona/workspace/sevoflurane-study-guide && python3 build_pdf.py 2>&1

Running Command

ls -lh /home/daytona/workspace/sevoflurane-study-guide/Sevoflurane_Study_Guide.pdf

Your study guide PDF is ready. Here's the download link:

Sevoflurane Study Guide

PDF Document · PDF


What's inside the PDF (11 sections, colour-coded):
SectionContent
CoverQuick-reference card - MAC, blood:gas coeff, key indications/contraindications at a glance
01Physical & pharmacokinetic properties + MAC modifiers table (increase vs decrease)
02Mechanism of action - GABA-A, NMDA, K⁺ channels explained
03Full organ system effects - CVS, respiratory, CNS, NMJ, renal, hepatic, uterus
04Indications with clinical notes
05Contraindications with reasons and actions
06Precautions - colour-coded boxes for MH, Compound A/fire risk, paediatric delirium, obstetrics, QT, renal
07Drug interactions table
084-agent volatile comparison table (sevoflurane column highlighted)
09Biotransformation + Compound A full detail
1017-point high-yield exam facts table
11Clinical dosing quick card by indication
The PDF is formatted for exam revision with colour-coded sections (navy/teal/green/red/amber), striped tables, and highlighted key points. Based on Miller's, Morgan & Mikhail's, Goodman & Gilman's, Barash, and Katzung.

Fluid for burns injury with Anesthesia implications

Reading File
Searching the medical library in parallel across headings and paragraphs for burns fluid and anaesthesia implications.
Finding Sources
Finding Sources
Searching PubMed

burn injury fluid resuscitation

Let me try broader searches in the paragraph FTS:
Finding Sources
Finding Sources
Excellent results. Now let me read the key sections in parallel - Morgan & Mikhail burns chapter, Miller's anaesthesia for burns, Sabiston surgery burns, and Tintinalli fluid resuscitation.
Reading File
Reading File
Reading File
Reading File
Now let me read more from Miller's burns chapter (anaesthesia drugs, monitoring, succinylcholine, pharmacology) and Morgan & Mikhail burns management section, and Sabiston on fluid resuscitation details:
Reading File
Reading File
Reading File
Excellent content. Now let me get the succinylcholine/NMBA section from Miller's, plus the monitoring and temperature sections:
Reading File
Reading File
Let me get the succinylcholine and NMBA content from Miller's, plus monitoring section:
Reading File
Finding Sources
Excellent - I now have comprehensive data. Let me get one more section - Miller's monitoring and temperature management for burns:
Reading File
I now have comprehensive material from Miller's, Morgan & Mikhail, Sabiston and Tintinalli. Let me compile the full answer.

Fluid Management in Burns & Anaesthesia Implications


PART 1 - PATHOPHYSIOLOGY OF BURN SHOCK

Understanding the why behind fluid therapy is essential for exams.

Why Massive Fluid is Lost

Within minutes to hours of a major burn (>20% TBSA), a profound systemic inflammatory response triggers:
  1. Massive release of vasoactive mediators - histamine, serotonin, prostaglandins, thromboxane, bradykinin, complement products
  2. Capillary hyperpermeability - both in burned AND non-burned tissue - large molecules (albumin, protein) leak into the interstitium
  3. ↑ Interstitial colloid osmotic pressure - draws intravascular water into tissues
  4. Burn oedema - the oedema fluid is isotonic and contains the same protein concentration as plasma
  5. Obligatory 20% decrease in both extracellular fluid AND plasma volume in the first 24 hours
Key fact: In a 50% TBSA burn, approximately 50% of the resuscitation fluid given is sequestered in non-burned tissues. The capillary leak is a systemic phenomenon, not just local.

Two Phases of Burns Physiology

PhaseTimingHaemodynamicsMetabolism
Ebb (shock) phase0-48 hrsLow CO, ↑ SVR, hypovolaemiaLow metabolic rate, hypothermia
Flow (hyperdynamic) phase48 hrs onwards↑↑ CO (supranormal), ↓ SVR↑↑ metabolic rate, hyperglycaemia, catabolism

PART 2 - ESTIMATING BURN SIZE (Rule of Nines)

Critical for calculating fluid volumes.
Body RegionAdult TBSAPaediatric (modified)
Head & neck9%18% (infant)
Each arm9%9%
Anterior trunk18%18%
Posterior trunk18%18%
Each leg18%14% (infant)
Perineum1%1%
Palmar surface of patient's hand (fingers spread) = approximately 1% TBSA - useful for irregular burns.
Important: Only partial-thickness (2nd degree) and full-thickness (3rd degree) burns are included in TBSA calculation for fluid resuscitation. First-degree (superficial/erythema only) burns are excluded.

PART 3 - FLUID RESUSCITATION FORMULAS

Parkland Formula (Most Widely Used)

4 mL × kg × % TBSA burned = total volume in first 24 hours
  • Fluid used: Lactated Ringer's (Hartmann's) - NOT normal saline, NOT colloid
  • Give ½ in first 8 hours (from time of injury, NOT from hospital arrival)
  • Give remaining ½ over next 16 hours

Modified Brooke Formula

2 mL × kg × % TBSA burned = total volume in first 24 hours
  • Same fluid and timing principle as Parkland
  • Lower volume, may reduce fluid creep risk
  • Some centres use this as the default

Galveston Formula (Paediatric)

5000 mL/m² burned + 1500 mL/m² total BSA (per 24 hours)
  • Children have higher surface area to volume ratio - more fluid required per kg
  • Add 5% dextrose to the IV fluid in children <30 kg to prevent hypoglycaemia
  • Target urine output: 1.0 mL/kg/h for children; 1–2 mL/kg/h for infants <1 year

Second 24 Hours

All protocols: Give half the total volume of first 24 hours in the second 24 hours. This is when colloid (albumin 5%) can be introduced - capillary permeability begins returning toward normal after 24 hours.

Endpoint of Resuscitation

Urine output is the primary clinical guide:
  • Adults: 0.5–1.0 mL/kg/h
  • Children: 1.0 mL/kg/h
  • Infants <1 year: 1–2 mL/kg/h
  • If UO >1.0 mL/kg/h in adults → slow the infusion
  • If UO <0.5 mL/kg/h → increase rate
Other markers used:
  • Lactate / base deficit (tissue perfusion)
  • Invasive haemodynamic monitoring in large burns
  • Bladder pressure (monitor for ACS)

PART 4 - FLUID CHOICE - WHAT AND WHAT NOT TO USE

FluidRecommendation
Lactated Ringer's (LR)Drug of choice - isotonic, contains lactate buffer, no hyperchloraemic acidosis
Normal saline (0.9% NaCl)AVOID in burn resuscitation - causes hyperchloraemic metabolic acidosis, increased AKI risk
Hypertonic salineAvoid - associated with higher incidence of acute kidney failure
Albumin / colloid (first 24 hrs)Not recommended in first 24 hrs - capillary leak means protein escapes into tissue worsening oedema
Albumin (after 24 hrs)Can be used in second 24 hrs when capillary permeability partially normalises
Hydroxyethyl starch (HES)AVOID - outcomes unchanged but risks real (AKI, coagulopathy)
Blood productsDeath more likely if used during acute resuscitation; reserve for operative bleeding
Fresh Frozen Plasma (FFP)Use in massive operative haemorrhage; balanced ratio with pRBCs (1:1) reduces mortality

PART 5 - COMPLICATIONS OF FLUID RESUSCITATION

Fluid Creep (Over-Resuscitation)

  • Defined as fluid volumes exceeding intended calculation due to response to haemodynamic changes unrelated to circulating volume
  • Common cause: sedation-induced hypotension treated with fluid rather than vasopressors
  • Consequence: ACS, pulmonary oedema, pneumonia, orbital compartment syndrome

Abdominal Compartment Syndrome (ACS)

  • Risk when fluids >6 mL/kg/% TBSA or circumferential abdominal burns
  • Diagnose: Measure bladder pressure (intra-abdominal pressure)
    • Instil 20 mL into bladder via Foley, zero transducer at pelvic brim, measure after 60 seconds
    • IAP >20 mmHg → decompression warranted
  • Treatment: abdominal decompression (note: risk of Pseudomonas infection near burned tissue)

Pulmonary Complications

  • Excess fluid → pulmonary oedema → ↓ ciliary activity + immunosuppression → pneumonia
  • ARDS can develop, especially with inhalation injury

Under-Resuscitation

  • Burn shock → organ failure → death
  • AKI is the most sensitive early marker

PART 6 - ANAESTHESIA IMPLICATIONS IN BURNS

A. Airway Management - The Highest Priority

When to intubate early (immediately):
  • Stridor, hoarseness, voice change
  • Singed nasal hairs / eyebrows
  • Soot in oropharynx / nasopharynx
  • Facial / neck burns
  • CO poisoning with altered consciousness
  • Burns in enclosed spaces
  • Inhalation injury suspected
Why early? - Progressive oedema: Airway oedema is maximal around 8–12 hours after injury and can progress over 48 hours. The airway that appears manageable initially can become completely obstructed within hours.
Airway approach:
  • If upper airway concern: awake fibreoptic intubation maintaining spontaneous ventilation
  • Children (cannot cooperate): ketamine sedation + fibreoptic or video laryngoscopy
  • Inhalational induction with sevoflurane (non-pungent, rapid) is suitable in uncooperative patients
  • Video laryngoscopy permits assessment of hypopharyngeal and glottic anatomy
  • Early tracheostomy if: prolonged mechanical ventilation anticipated, massive facial/neck burns, inhalation injury, large TBSA, chronic pulmonary disease
Securing the ETT:
  • Adhesive tape is unsuitable in facial burns (injures grafts/wounds)
  • Use: circumferential tie around head, wire secured to tooth, arch bars
  • Use cuffed ETTs in paediatric burns regardless of age (safe and recommended)
  • ETT cuff may need periodic readjustment as airway oedema fluctuates

B. Carbon Monoxide (CO) & Cyanide Poisoning

CO poisoning:
  • CO binds Hb with ~250× affinity vs O₂ → carboxyhemoglobin (HbCO) → left shift of O₂-Hb curve + impaired O₂ delivery
  • SpO₂ is FALSELY NORMAL with standard pulse oximetry (cannot distinguish HbO₂ from HbCO)
  • Diagnose with ABG/VBG co-oximetry measuring HbCO directly
  • HbCO >10% = clinically significant
  • HbCO >20% → intubate + 100% FiO₂ (reduces CO half-life from 4–5 hrs to ~60 min)
  • HbCO >40% → consider hyperbaric oxygen
Cyanide poisoning (from burning plastics/synthetics):
  • Suspect in: exposure to burning synthetics, unexplained lactic acidosis, HbCO normal or mild
  • Treatment: hydroxocobalamin (Cyanokit) IV - drug of choice; sodium thiosulphate as alternative

C. Succinylcholine - THE CRITICAL ANAESTHETIC RULE IN BURNS

SUCCINYLCHOLINE IS CONTRAINDICATED IN BURNS BEYOND 48–72 HOURS AFTER INJURY
Mechanism:
  • Burn injury causes upregulation of extrajunctional acetylcholine receptors (including fetal-type and α7 neuronal-type receptors) throughout the muscle membrane
  • On depolarisation with succinylcholine, these proliferated receptors release massive amounts of potassium
  • This causes life-threatening hyperkalaemia → cardiac arrest
Timeline:
  • Risk begins: 48–72 hours after burn (some evidence from 24–48 hours)
  • Risk peaks: ~7–10 days
  • Risk persists: potentially up to 463 days after injury in large burns (documented resistance to NMBAs for over a year)
  • Prolonged by: immobilisation, contractures, ICU myopathy, malnutrition
Alternative for RSI:
  • Rocuronium 1.2–1.5 mg/kg (modified RSI dose - higher than standard 0.6 mg/kg)
  • Onset in burns: ~90 seconds (vs <60 seconds in non-burned patients at standard doses)
  • Duration is variable - neuromuscular monitoring is essential
  • Reversal: Sugammadex can reverse high-dose rocuronium reliably

D. Resistance to Non-Depolarising Muscle Relaxants (NDMRs)

The same upregulation that causes succinylcholine hyperkalaemia also causes resistance to NDMRs because:
  1. ↑ acetylcholine receptors → more receptors available → need more drug to block
  2. ↑ binding to alpha-1 acid glycoprotein (AAG) - burned patients have elevated AAG
  3. ↑ hepatic and adrenal elimination during hyperdynamic phase
Practical implication:
  • Larger doses needed
  • Faster offset (shorter duration)
  • Neuromuscular monitoring (TOF) is mandatory in all burns patients receiving NMBAs
  • The degree of resistance correlates with burn size and time after injury

E. Induction Agents & IV Anaesthetics

Ketamine - Drug of Choice in Burns
PropertyRelevance in Burns
Haemodynamic stability↑ sympathetic stimulation → maintains BP/HR in hypovolaemic patient
Preserves airway reflexesIdeal for procedures without intubation (dressing changes, brief procedures)
BronchodilationUseful if inhalation injury / bronchospasm
NMDA antagonismPrevents central sensitisation, reduces opioid tolerance, reduces wind-up
Anti-inflammatoryPotential benefit in burns/sepsis
Peripheral vasoconstrictionMay reduce blood loss, reduces hypothermia
Caution: In patients with persistently elevated catecholamines (late burns), β-adrenoreceptors are downregulated. Bolus ketamine can then unmask direct myocardial depression → hypotension.
Propofol:
  • ↑ clearance and ↑ volume of distribution during hyperdynamic phase
  • Requires larger bolus doses and higher infusion rates to achieve therapeutic levels
  • Monitor haemodynamic consequences of larger doses carefully
Volatile Agents:
  • Sevoflurane preferred for inhalational induction (non-pungent, rapid)
  • Choice of volatile agent does not appear to influence outcome
  • Isoflurane commonly used for maintenance

F. Opioid Analgesics in Burns

  • Mainstay of analgesia - dose-dependent, titratable
  • Background pain: oral morphine (SR), fentanyl patch, methadone
  • Procedural pain: IV fentanyl, alfentanil (rapid onset, short-acting)
  • Tolerance develops rapidly - dose escalation expected
  • Midazolam combined with opioids reduces anticipatory anxiety for wound care
  • Midazolam long-term use may exaggerate opioid tolerance

G. Pharmacokinetic Changes in Burns

Early phase (hypovolaemia/shock - first 24-48 hrs):
  • ↓ cardiac output → ↓ hepatic blood flow
  • Drugs highly extracted by liver (propofol, fentanyl): ↓ clearance → ↑ plasma levels
Hyperdynamic phase (48 hrs onwards):
  • ↑↑ cardiac output, ↑ renal blood flow, ↑ hepatic blood flow
  • High extraction drugs: ↑ clearance
  • Antibiotics (gentamicin, cephalosporins): enhanced renal elimination → may need higher doses
  • Low extraction drugs (diazepam): clearance unchanged by blood flow but affected by ↓ albumin (Phase I reactions impaired)
  • Phase I hepatic reactions (oxidation, demethylation) are impaired post-burn → avoid diazepam
  • Phase II reactions (glucuronidation, sulfation) relatively spared → lorazepam preferred over diazepam
  • Drug may also be lost through the burn wound and with intraoperative blood loss

H. Monitoring

Standard monitoring + additional considerations:
MonitorConsideration in Burns
SpO₂Unreliable in CO poisoning; may be inaccurate on burned digits
ABG co-oximetryEssential for HbCO, MetHb measurement
Urinary catheterMandatory - primary guide for fluid titration (UO 0.5–1.0 mL/kg/h)
TemperatureContinuous monitoring - burns patients cannot thermoregulate
Invasive arterial lineEssential in major burns; may need to site through burned tissue
Central venous accessFor large-bore access; may be sited through burned skin if no alternative
TOF neuromuscular monitoringMandatory if NMBAs used
Bladder pressureIf fluid creep or ACS suspected (IAP >20 mmHg is threshold)
Intraoperative glucoseHyperglycaemia is common - insulin infusion often required

I. Temperature Management

Burns patients have severely impaired thermoregulation:
  • Loss of skin insulation
  • Vasodilation from anaesthesia + alcohol skin prep worsens heat loss
  • OR rooms for burn excision should be warmed to 37–40°C
  • Use warming blankets, fluid warmers, heated humidified gases
  • Hypothermia → coagulopathy → increased blood loss → vicious cycle

J. Intraoperative Blood Loss & Fluid Management During Excision

  • Blood loss during burn excision: 3.5–5% of blood volume per 1% TBSA excised
  • This can be massive - transfusion triggers must be defined pre-operatively
  • Difficulties in assessing blood loss:
    • Blood cannot be collected in suction canisters efficiently
    • Sponges pre-soaked with haemostatic agents
    • Bleeding under bulky dressings is not visible
Strategies to reduce blood loss:
  1. Topical/subcutaneous dilute epinephrine to burn wound and donor sites
  2. Tourniquets + limb elevation for extremity excisions
  3. Compression dressings
  4. Topical thrombin and fibrinogen
  5. Brisk operative pace - less time = less bleeding
Transfusion strategy:
  • Balanced ratio FFP:pRBC (1:1) in massive haemorrhage - reduces coagulopathy
  • Use thromboelastometry (ROTEM/TEG) to guide targeted blood product use
  • Restrictive transfusion strategy is well-tolerated and reduces transfusion requirements without increasing complications
  • Platelets: threshold unclear; guided by clinical bleeding + TEG
  • Tranexamic acid: evidence from burns surgery supports its use (meta-analysis, PMID 37268542, 2023)

K. Gastric Emptying & Aspiration Risk

  • Sepsis, intestinal oedema, opioids → delayed gastric emptying
  • If ileus suspected → rapid-sequence induction (RSI)
  • Avoid LMA if decreased chest/abdominal compliance (compressed lung volumes) → gas redirection to stomach → regurgitation risk

L. Regional Anaesthesia in Burns

  • Applicable for extremity burns and donor sites
  • Protein binding changes alter local anaesthetic pharmacokinetics
  • Risk of neurotoxicity/cardiotoxicity is unchanged but critically ill patients tolerate LA toxicity less
  • Liposomal bupivacaine (extended-release): potential advantage for longer-acting infiltration
  • Central neuraxial techniques: technically difficult in spinal burns; concern about infection through burned skin

PART 7 - INHALATION INJURY

Inhalation injury dramatically worsens prognosis and significantly alters fluid requirements.
Three components:
  1. Upper airway thermal injury - direct heat (usually above glottis as lower airway is protected by vocal cords)
  2. Lower airway chemical injury - toxic combustion products (aldehydes, HCN, acrolein) cause mucosal sloughing, cast formation, airway obstruction
  3. Systemic toxin poisoning - CO, cyanide
Diagnosis:
  • Clinical: enclosed space, soot in airway, hoarseness, stridor, carbonaceous sputum
  • Confirm with: direct laryngoscopy/bronchoscopy - gold standard
  • CXR may be initially normal
  • ABG with co-oximetry
Impact on fluids:
  • Inhalation injury significantly increases fluid requirements - add 30–50% to calculated Parkland volume
  • Fluid creep more likely in patients requiring heavy sedation for mechanical ventilation

PART 8 - SPECIAL POPULATIONS

Paediatric Burns

  • Use Galveston formula: 5000 mL/m² burned + 1500 mL/m² total BSA
  • Add 5% dextrose in IV fluid for children <30 kg (prevent hypoglycaemia)
  • Target UO: 1.0–2.0 mL/kg/h (higher than adults)
  • Succinylcholine contraindicated >48–72 hrs (same mechanism)
  • Cuffed ETTs recommended regardless of age
  • Emergence delirium common with sevoflurane - use multimodal analgesia

Electrical Burns

  • Entry and exit wounds visible; internal tissue damage far greater than surface appearance
  • Start with Parkland formula but modify upwards for deep tissue destruction
  • Myoglobinuria (dark urine) → target UO 1–2 mL/kg/h until urine clears (↑ tubular flow prevents myoglobin cast formation)
  • Sodium bicarbonate may be added to alkalinise urine and increase myoglobin solubility
  • Cardiac monitoring mandatory: risk of arrhythmias (VF, VT, QT prolongation)
  • Risk of spinal cord injury (delayed) in high-voltage contact

Chemical Burns

  • Continue irrigation pre-hospital and in ED (minimum 20–30 min)
  • Alkali burns (lye, cement) penetrate more deeply and cause ongoing saponification injury
  • HF (hydrofluoric acid): fluoride chelates Ca²⁺ → systemic hypocalcaemia → life-threatening arrhythmias; treat with topical/systemic calcium gluconate

HIGH-YIELD EXAM SUMMARY TABLE

TopicKey Fact
Parkland formula4 mL × kg × %TBSA; ½ in 8 hrs, ½ in 16 hrs; LR only
Modified Brooke2 mL × kg × %TBSA; same timing
Paediatric (Galveston)5000 mL/m² burned + 1500 mL/m² BSA
Fluid choiceLR - NOT NS, NOT HES, NOT colloid in first 24 hrs
Endpoint of resuscitationUO 0.5–1.0 mL/kg/h adults; 1.0 mL/kg/h children
SuccinylcholineCONTRAINDICATED after 48–72 hrs (hyperkalaemia → cardiac arrest)
NDMRsResistance - need higher doses (rocuronium 1.2–1.5 mg/kg for RSI)
SpO₂ in CO poisoningFalsely normal - use ABG co-oximetry
Airway in burnsIntubate early before oedema progresses
KetamineDrug of choice - haemodynamic stability, airway preserved, NMDA antagonist
Blood loss in excision3.5–5% blood volume per 1% TBSA excised
TemperatureOR warmed to 37–40°C; warming blankets + fluid warmers
ACS thresholdIAP >20 mmHg (bladder pressure) → decompression
Fluid creepExcess fluid → ACS + pulmonary complications
Inhalation injuryAdd 30–50% to Parkland volume; early intubation
Phase I hepatic reactionsImpaired in burns - avoid diazepam; use lorazepam
Propofol in hyperdynamic phase↑ clearance → need higher doses
Myoglobinuria (electrical)Target UO 1–2 mL/kg/h; alkalinise urine

Sources:
  • Morgan & Mikhail's Clinical Anesthesiology, 7e - Chapter 39 (Burns), pp. 1557–1562
  • Miller's Anesthesia, 10e - Chapter 83 (Anaesthesia for Burns), pp. 12367–12390
  • Sabiston Textbook of Surgery, 21e - Chapter 43 (Burns), pp. (resuscitation section)
  • Tintinalli's Emergency Medicine - Chapter 217 (Thermal Burns), fluid resuscitation section
  • Rosen's Emergency Medicine - Burns chapters
  • Fijany et al., Tranexamic acid in burn surgery: Meta-analysis. Burns. 2023 Sep. [PMID: 37268542]
This is a shared conversation. Sign in to Orris to start your own chat.